Opendata, web and dolomites

AURORAX SIGNED

Advancing cancer detection through metabolism-based diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AURORAX project word cloud

Explore the words cloud of the AURORAX project. It provides you a very rough idea of what is the project "AURORAX" about.

diagnostics    aur87    recurrences    signed    effectiveness    perform    patient    disease    benefit    letter    regular    cancer    12    urologists    letters    easily    imaging    annual    follow    blood    introduce    sweden    regulatory    metastatic    elypta    treatment    exceptional    rates    monitoring    diagnosed    200b    sales    biopsy    139    drop    starting    launch    demonstrated    first    basis    stages    recurrence    urine    pharmaceutical    business    detected    20    obtain    once    financially    validation    ing    trials    too    limited    renal    frequent    clinical    niche    former    survival    detect    ruo    independent    enter    outcomes    solid    metabolism    generate    aurorax    receive    metabolite    companies    ups    trial    competition    indications    laboratories    rcc    scalable    sensitivity    patients    cell    frequency    oncologist    quantification    platform    risks    carcinoma    significantly    algorithmic    signature    surveil    stage    risk    strategy    radiation    surgery    terminal    multiple    clearance    liquid    market    optimize    expressing    small    off    improves   

Project "AURORAX" data sheet

The following table provides information about the project.

Coordinator
ELYPTA AB 

Organization address
address: REGERINGSGATAN 65, 3TR
city: STOCKHOLM
postcode: 111 56
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 3˙346˙674 €
 EC max contribution 2˙342˙671 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELYPTA AB SE (STOCKHOLM) coordinator 2˙342˙671.00

Map

 Project objective

Former cancer patients receive regular follow-ups to detect recurrences at early stages and optimize treatment outcomes. The follow-up frequency is currently limited by costs and radiation risks of imaging approaches used to surveil for recurrences, resulting in recurrences being detected too late – often resulting in terminal disease. Of the 139.000 annual Renal Cell Carcinoma (RCC) patients, 20% are diagnosed with a metastatic recurrence within 5 years after surgery. Once metastatic, RCC survival rates drop to 12% over 5 years survival. Elypta, Sweden, has developed the first metabolism-based liquid biopsy to detect early-stage recurrences. The quantification of a metabolite signature in blood or urine and an algorithmic analysis allows for exceptional sensitivity, a low cost of the platform and significantly improves on imaging approaches in cost and risk, enabling frequent patient follow-up. Elypta’s technology has been demonstrated in small clinical trials and its cost effectiveness assessed by two independent companies. Elypta’s platform is easily scalable to other cancer indications and applications such as treatment monitoring, as demonstrated in multiple small trials. Starting in the niche RCC market with limited competition, Elypta now requires clinical evidence for a product launch within RCC. The business strategy focuses on distribution and sales through clinical laboratories, which will benefit financially off sales. During the AURORAX, Elypta will 1) perform a clinical validation trial (AUR87) to generate strong clinical evidence, 2) obtain regulatory clearance in the EU and the US and 3) introduce the product for research use only (RUO) and after clinical validation enter the RCC diagnostics market in EU. As users of the platform, oncologist and urologists have all signed letters of support. A pharmaceutical partner has also signed a letter of support, expressing their interest in RUO use of the platform, providing a solid basis in the emerging liquid biopsy market (€200B market).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURORAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURORAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

TANDEM (2019)

Tuneable Acoustic Noise DampEning Material

Read More  

CoLumbo (2019)

AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRI

Read More